Marksans Pharma Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/c1wz71lqjat9ayt8pn3ogrbr.pdf

Key Takeaways


Teva Acquisition: The Drag and the Payoff

Mark Saldanha: "So obviously like I mentioned in my previous concalls, there will be some pain before any gain..."

US Market: Stabilization and Ambition

Mark Saldanha: "Well market size in US is huge and we expect to double our revenue in the next couple of years, but we are relatively very small in the US market. So that gives us the potential for growth."

UK and Formulation Markets: The Growth Engine


Margins: Current Strength, Full-Year Caution


Backward Integration and Capacity


M&A and Capital Allocation

Mark Saldanha: "We are in dialogue Viraj with actually two target companies, but nothing concrete to highlight, we are far away from any pen coming to paper per se, so I think it is too early to discuss anything relevant because these M&As and 90% of the time the probability factors are they do not go through."

Guidance & Commitments

CommitmentSpecificsTimeline
Full-year revenueCross ₹2,000 Crores in FY2024FY2024 (extrapolated from Q1 run rate)
Full-year EBITDA marginRange-bound at 17–19%FY2024
Gross marginRemain at current level (~51.5%)Throughout FY2024
Teva plant revenue₹40–₹45 croresBy end of FY2024
Teva plant break-evenFull optimization and break-evenQ1 FY25
Teva substantial revenueMeaningful contributionFY2025
US revenueDouble from current levelNext couple of years
US product launches3–4 launches including Advil dual action equivalentFY2024
Backward integration: first DMFFile first DMFSeptember 2024
Backward integration: DMF countAt least two DMFs filedFY2024
US FDA Goa EIR reportReport received after answering observationsCouple of months from Q1-end
API pricing environmentStability expectedAt least next 12 months
EBITDA margin medium-termImprove to 21–22% as Teva capacity utilization risesAs Teva ramps (no date)
Revenue growth trajectoryAt least 15% revenue growthNext two to three years

Key Metrics

MetricQ1 FY24
Operating revenue₹500 cr, +15.3% YoY
US and North America revenue₹193.3 cr, +11.2% YoY
UK and new formulation markets revenue₹225.9 cr, +24.8% YoY
Australia and New Zealand revenue₹58.6 cr, +11.4% YoY
Rest of the world revenue₹22.2 cr
Gross margin51.5%, +95 bps YoY
EBITDA₹102 cr, +39.9% YoY and -6.9% QoQ
EBITDA margin20.4%
Profit after tax₹70.4 cr, +17% YoY
EPS₹1.52
Cash from operations₹34.3 cr
Free cash flow-₹47.2 cr, on account of high capex in the quarter
Capex incurred₹81.5 cr
R&D spend₹8.46 cr, 1.7% of sales
Total cash balance₹636 cr as of 30th June 2023
Capacity utilization (excl. Teva)~70%
Teva facility cost loading in P&L~₹11 cr in the quarter
FY24 revenue guidanceCross ₹2,000 cr
FY24 EBITDA margin guidance17–19%
Expected Teva revenue contribution in FY24₹40–50 cr
UK tax rate25%, increased from 19%
Working capital cycle~120 days